This study indicates that TRX2 suppresses HCT116 colorectal cancer cell migration in a Rab35-dependent manner and that exosome-mediated TRX2 inhibition inhibits cell migration, which provides new ideas for the clinical treatment of CRC. This evidence concerns the gene TXN2 and colorectal carcinoma.